CCA
RANI icon

Cygnus Capital Advisors’s Rani Therapeutics RANI Stock Holding History

Cygnus Capital Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85 Buy
+115,649
New +$148K 0.06% 64

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return

Cygnus Capital Advisors's RANI Position: Q1 2026 in Review

Cygnus Capital Advisors opened a new position in Rani Therapeutics (RANI) in Q1 2026: 115,649 shares worth $85. The stake represents 0.06% of the portfolio and ranks #64 among its holdings.

74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Cygnus Capital Advisors held 115,649 shares of Rani Therapeutics worth $85 as of Q1 2026.
  • Rani Therapeutics was a new Cygnus Capital Advisors position in Q1 2026.
  • Rani Therapeutics made up 0.06% of Cygnus Capital Advisors's portfolio in Q1 2026, its #64 holding.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.